Seer Secures European Patent, U.S. International Trade Commission Probe Launched Into Alleged Nanomics Infringement

Seer, Inc. (NASDAQ: SEER ), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced two significant developments that reinforce the strength of the intellectual property portfolio protecting its proprietary nanoparticle protein enrichment technology.

These milestones underscore Seer's leadership in proteomics, validate the innovation behind its differentiated platform, and reflect the company's continued commitment to protecting the technologies that are advancing the future of proteomics.

On June 25, 2026, the European Patent Office (EPO) concluded that European Patent No.

EP4056263 will be maintained on the basis of claims covering particle-based enrichment for proteomics, and on June 29, 2026, the U.S.

International Trade Commission (ITC) instituted an investigation into the importation by Nanomics Biotechnology Co., Ltd. of products that Seer alleges infringe five of its U.S. patents.

The EPO outcome followed an opposition that sought revocation of EP4056263 by an unnamed opponent.

After the proceedings, the EPO determined that the patent would be maintained, with claims broadly covering the particle-based approach at the core of Seer's proteomics technology.

A written decision is expected in approximately two months.

EP4056263 is owned by The Brigham and Women's Hospital and exclusively licensed to Seer.